A Study to derive normative distribution of CIMT (Cancer Immunotherapy) and to determine its cOrrelation with cardiovascular Risk factors.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Carotid Intima- Media Thickness
- Registration Number
- CTRI/2012/09/003012
- Lead Sponsor
- AstraZeneca Pharma India Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1500
Inclusion Criteria
Provision of subject informed consent
Female or male aged 30 years and over
Exclusion Criteria
1.Subjects with established cardiovascular event
2.History of acute or chronic GI, renal, hepatic, CNS, respiratory, infectious, or psychiatric diseases that may affect the outcome of the study
3.Intake of lipid lowering drug in the past 3 months
4.Subjects with known hypersensitivity to carotid bulb
5.Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study
6.Pregnant or lactating women
7.If participating in any clinical study, the subject cannot take part in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To obtain distribution and correlates of CIMT in subjects without established cardiovascular disease.Timepoint: at visit 1
- Secondary Outcome Measures
Name Time Method To examine association between: <br/ ><br> <br/ ><br>â?¢CIMT values and demographic characteristics <br/ ><br>â?¢CIMT values and CVD risk factors <br/ ><br>Timepoint: at visit 1